ImmunityBio (IBRX) stock rose 6% pre-market after founder Patrick Soon-Shiong highlighted data linking COVID-related immune cell loss to breast cancer spread. This spotlights Anktiva, an immunotherapy that activates immune cells, with findings set to be presented at a cancer summit. ImmunityBio is testing Anktiva for long COVID and recently secured $100 million in financing.